|
ZYUS Life Sciences Corporation, a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 12,616,704, entitled Cannabichromene Formulation For Pain Management. The patent, held by ZYUS' wholly owned subsidiary, ZYUS Life Sciences Inc., is based on International Patent Application No. PCT/CA2021/050430 and covers a novel, non-intoxicating approach to pain management.
This represents the company's second US patent in pain management, further strengthening its intellectual property portfolio. The company's first US patent supports ZYUS' lead drug candidate, Trichomylin softgel capsules, a proprietary fixed-dose combination for pain management by delivering a balanced ratio of cannabinoids, which includes cannabichromene (CBC).
The newly issued patent relates to the company's second drug candidate, further expanding its pipeline of novel, proprietary, non-opioid therapies and supports ongoing clinical research targeting neuropathic pain, including peripheral neuropathy, such as diabetic and cancer-related neuropathies. These indications are consistent with those covered under the company's first patent, reinforcing ZYUS' focused approach to pain management.
The issuance of the US patent further strengthens the continued development of the company's second drug candidate, for which Investigational New Drug (IND)-enabling studies have been completed to support the potential initiation of clinical trials in the United States. The patent provides additional intellectual property protection alongside potential regulatory exclusivity for CBC, whether as monotherapy or within its lead drug product, Trichomylin softgel capsules, subject to regulatory determination by the US Food and Drug Administration (FDA) at the time of marketing authorization.
"The issuance of this US patent further validates our commitment to advancing a differentiated portfolio of novel non-opioid pain drugs," said Brent Zettl, president and CEO of ZYUS. "We remain focused on developing innovative treatment options to address significant unmet needs in chronic and neuropathic pain."
ZYUS is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value.
|